MA47119A - Livraison de protéines au moyen de bactéries à virulence atténuée - Google Patents

Livraison de protéines au moyen de bactéries à virulence atténuée

Info

Publication number
MA47119A
MA47119A MA047119A MA47119A MA47119A MA 47119 A MA47119 A MA 47119A MA 047119 A MA047119 A MA 047119A MA 47119 A MA47119 A MA 47119A MA 47119 A MA47119 A MA 47119A
Authority
MA
Morocco
Prior art keywords
protein
delivery
bacteria
mixed virulence
mixed
Prior art date
Application number
MA047119A
Other languages
English (en)
Other versions
MA47119B1 (fr
Inventor
Marlise Amstutz
Simon Ittig
Christoph Kasper
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of MA47119A publication Critical patent/MA47119A/fr
Publication of MA47119B1 publication Critical patent/MA47119B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01011—Aspartate-semialdehyde dehydrogenase (1.2.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA47119A 2016-12-20 2017-12-20 Administration de protéine à base de bactéries à virulence atténuée MA47119B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205439 2016-12-20
PCT/EP2017/083853 WO2018115140A2 (fr) 2016-12-20 2017-12-20 Livraison de protéines au moyen de bactéries à virulence atténuée

Publications (2)

Publication Number Publication Date
MA47119A true MA47119A (fr) 2019-10-30
MA47119B1 MA47119B1 (fr) 2021-09-30

Family

ID=57629346

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47119A MA47119B1 (fr) 2016-12-20 2017-12-20 Administration de protéine à base de bactéries à virulence atténuée

Country Status (28)

Country Link
US (2) US11518789B2 (fr)
EP (2) EP3957645A1 (fr)
JP (1) JP6976351B2 (fr)
KR (1) KR102569949B1 (fr)
CN (2) CN110325545B (fr)
AU (1) AU2017384611B2 (fr)
BR (1) BR112019012338A2 (fr)
CA (1) CA3046852A1 (fr)
CL (1) CL2019001698A1 (fr)
CO (1) CO2019006675A2 (fr)
CY (1) CY1124488T1 (fr)
DK (1) DK3559022T3 (fr)
EA (1) EA201991157A1 (fr)
ES (1) ES2886672T3 (fr)
HR (1) HRP20211516T1 (fr)
HU (1) HUE055832T2 (fr)
IL (1) IL267346A (fr)
LT (1) LT3559022T (fr)
MA (1) MA47119B1 (fr)
MX (1) MX2019007264A (fr)
MY (1) MY192537A (fr)
PE (1) PE20191356A1 (fr)
PH (1) PH12019550092A1 (fr)
PL (1) PL3559022T3 (fr)
PT (1) PT3559022T (fr)
RS (1) RS62303B1 (fr)
SI (1) SI3559022T1 (fr)
WO (1) WO2018115140A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3660034A1 (fr) 2014-05-21 2020-06-03 Universität Basel Administration de protéines à base de bactéries
BR122023024697A2 (pt) 2015-11-19 2023-12-26 Universität Basel Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana
ES2830251T3 (es) 2015-11-19 2021-06-03 Univ Basel Administración de proteínas basada en bacterias
CA3011283A1 (fr) 2016-01-11 2017-07-20 Synlogic Operating Company, Inc. Microorganismes programmes pour produire des immunomodulateurs et des agents therapeutiques anticancereux dans des cellules tumorales
SI3559022T1 (sl) 2016-12-20 2021-11-30 Universitaet Basel Dostava proteina na osnovi virulentno oslabljenih bakterij
WO2020051197A1 (fr) * 2018-09-06 2020-03-12 Dana-Farber Cancer Institute, Inc. Nucléotidyltransférases de type cgas/dncv et leurs utilisations
CN109825464B (zh) * 2019-01-17 2021-06-15 浙江海洋大学 敲除t6ss-1基因簇的杀香鱼假单胞菌鱼用减毒疫苗
EP4045672A4 (fr) * 2019-10-18 2023-11-22 University of Virginia Patent Foundation Compositions et procédés de production de réponses immunitaires améliorées et production rapide d'anticorps
US20230364162A1 (en) * 2020-09-28 2023-11-16 The Regents Of The University Of Michigan Methods and compositions for intestinal inflammation
IL302334A (en) * 2020-10-27 2023-06-01 T3 Pharmaceuticals Ag Providing bacteria-based protein
WO2022164937A1 (fr) * 2021-01-26 2022-08-04 Christopher Bradley Traitement du cancer à l'aide d'antigènes de vaccination par virus à médiation par arnm délivrés par des bactéries atténuées
CN112852698B (zh) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用
CA3210774A1 (fr) * 2021-03-25 2022-09-29 Simon ITTIG Combinaisons pharmaceutiques pour le traitement du cancer
CN117425671A (zh) * 2021-03-25 2024-01-19 T3制药股份公司 用于治疗癌症的药物组合
CN113480611B (zh) * 2021-06-28 2022-12-02 武汉大学 Rig-i的半胱天冬酶激活募集结构域抗病毒多肽、载体及其在制备抗病毒药物中的应用
CN113699088B (zh) * 2021-08-27 2023-09-15 集美大学 一株溶藻弧菌pstS基因稳定沉默菌株及其应用
CN114181881A (zh) * 2021-12-15 2022-03-15 浙江农林大学 基于氨基酸改造的新型减毒单增李斯特菌构建方法及应用
WO2023164454A2 (fr) * 2022-02-22 2023-08-31 Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Compositions et procédés pour une transformation de plante médiée par rhizobium améliorée
CN115109858A (zh) * 2022-06-07 2022-09-27 宁波大学 一种美人鱼发光杆菌美人鱼亚种的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
AU5209399A (en) 1998-07-10 2000-02-01 Cornell Research Foundation Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
US6291245B1 (en) * 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
WO2002026819A2 (fr) * 2000-09-26 2002-04-04 Roger Williams Hospital Vaccins b.c.g. de recombinaison aux fins du traitement et de la prevention du cancer
US20040147719A1 (en) 2001-03-26 2004-07-29 Guy Cornelis Type III bacterial strains for use in medicine
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
EP1943344A2 (fr) * 2005-10-04 2008-07-16 The Ludwig Institute for Cancer Research Methodes permettant de stimuler une reponse immunitaire au moyen d'un systeme de distribution d'antigenes bacteriens
WO2008019183A2 (fr) 2006-05-18 2008-02-14 The Regents Of The University Of California Production de biopolymères et de protéines au moyen de systèmes de sécrétion de type iii de bactéries à gram négatif
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2268313A2 (fr) 2008-03-17 2011-01-05 Universitätsklinikum Münster Protéine yopm utilisée comme véhicule pour les molécules cargo et comme agent thérapeutique biologique pour l immunomodulation de réactions inflammatoires
AU2015227479B2 (en) * 2008-11-21 2017-05-04 Københavns Universitet (University Of Copenhagen) Priming of an immune response
US9951340B2 (en) * 2013-03-07 2018-04-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
CN105722982A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
EP3660034A1 (fr) 2014-05-21 2020-06-03 Universität Basel Administration de protéines à base de bactéries
ES2830251T3 (es) 2015-11-19 2021-06-03 Univ Basel Administración de proteínas basada en bacterias
BR122023024697A2 (pt) 2015-11-19 2023-12-26 Universität Basel Usos de uma cepa bacteriana gram-negativa recombinante de virulência atenuada e de uma composição farmacêutica compreendendo a referida cepa bacteriana
SI3559022T1 (sl) 2016-12-20 2021-11-30 Universitaet Basel Dostava proteina na osnovi virulentno oslabljenih bakterij

Also Published As

Publication number Publication date
MA47119B1 (fr) 2021-09-30
SI3559022T1 (sl) 2021-11-30
EP3559022B1 (fr) 2021-06-30
CN118006531A (zh) 2024-05-10
BR112019012338A2 (pt) 2019-11-26
MY192537A (en) 2022-08-26
PT3559022T (pt) 2021-08-19
CA3046852A1 (fr) 2018-06-28
NZ754510A (en) 2024-02-23
MX2019007264A (es) 2019-11-18
CY1124488T1 (el) 2022-07-22
US20200123207A1 (en) 2020-04-23
DK3559022T3 (da) 2021-09-27
CN110325545A (zh) 2019-10-11
PL3559022T3 (pl) 2021-12-20
EP3559022A2 (fr) 2019-10-30
LT3559022T (lt) 2021-08-25
WO2018115140A2 (fr) 2018-06-28
US11518789B2 (en) 2022-12-06
PH12019550092A1 (en) 2020-03-09
KR20190097154A (ko) 2019-08-20
AU2017384611B2 (en) 2022-10-27
AU2017384611A1 (en) 2019-07-04
IL267346A (en) 2019-08-29
CN110325545B (zh) 2024-02-09
ES2886672T3 (es) 2021-12-20
JP2020501609A (ja) 2020-01-23
PE20191356A1 (es) 2019-10-01
EP3957645A1 (fr) 2022-02-23
US20230250138A1 (en) 2023-08-10
WO2018115140A3 (fr) 2018-08-09
KR102569949B1 (ko) 2023-08-24
HUE055832T2 (hu) 2021-12-28
RS62303B1 (sr) 2021-09-30
CL2019001698A1 (es) 2020-01-24
HRP20211516T1 (hr) 2021-12-24
EA201991157A1 (ru) 2020-01-16
CO2019006675A2 (es) 2019-09-18
JP6976351B2 (ja) 2021-12-08

Similar Documents

Publication Publication Date Title
MA47119A (fr) Livraison de protéines au moyen de bactéries à virulence atténuée
BR112017020491A2 (pt) composições e métodos para distribuição de agentes de biomacromolécula.
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
BR112016022814A2 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
DK3532029T3 (da) Flydende farmaceutisk sammensætning
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
DK3371179T3 (da) Hidtil ukendte cryptophycin-forbindelser og konjugater, deres fremstilling og terapeutisk anvendelse heraf
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA202091567A1 (ru) Химерные белки мти
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
IL265831A (en) Preparations and methods for protein expression and administration
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
DK3316856T3 (da) Blandede formuleringer
IL283229A (en) High concentration protein formulation
DK3247394T3 (da) Farmaceutisk formulering omfattende anti-egfr-antistof
DK3548052T3 (da) Anvendelse af en bakterieblanding til behandling af fodinfektioner hos hovdyr
DK3484545T3 (da) Medicinafgivelsesanordning
CL2017000016A1 (es) Administración intradérmica de una composición de inmunoglobulina g.
FR3023484B1 (fr) Preparations antifongiques destinees au traitement local des onychomycoses
DK3481370T3 (da) Farmaceutisk sammensætning omfattende benzydamin